Dr Nigel Strauss

Experts / Dr Nigel Strauss

Psychiatrist and Clinical Associate at The Centre of Mental Health, Swinburne University of Technology

Dr. Strauss is a clinical and research psychiatrist with a special interest in Psychedelic Assisted Psychotherapy. He is a MAPS trained therapist and currently an Investigator in 5 PAT trials in Melbourne. He is also currently a psychedelic psychotherapist using psilocybin in 2 of these trials. He is also an Honorary Senior Consultant at St Vincent’s Hospital Melbourne.

Psychedelic medicine is on its way. Here’s what you need to know

Many people in Australia, including psychiatrists, were surprised when earlier this year the medicines regulator down-scheduled MDMA, known colloquially as ecstasy, and psilocybin, from magic mushrooms.

Psychedelic medicine is on its way. Here’s what you need to know

Many people in Australia, including psychiatrists, were surprised when earlier this year the medicines regulator down-scheduled MDMA, known colloquially as ecstasy, and psilocybin, from magic mushrooms.

By Dr Nigel Strauss, Prof Colleen Loo, Prof David Jonathan Castle, Prof Steve Kisely

Clinical Articles

Art of medicine

Dr Nigel Strauss

Psychiatrist and Clinical Associate at The Centre of Mental Health, Swinburne University of Technology

More from this expert

Psychedelic medicine is on its way. Here’s what you need to know

Many people in Australia, including psychiatrists, were surprised when earlier this year the medicines regulator down-scheduled MDMA, known colloquially as ecstasy, and psilocybin, from magic mushrooms.

Psychedelic medicine is on its way. Here’s what you need to know

Many people in Australia, including psychiatrists, were surprised when earlier this year the medicines regulator down-scheduled MDMA, known colloquially as ecstasy, and psilocybin, from magic mushrooms.

Get the app

Site

Company

Connect

Legal

Discover

Healthed

Upcoming Healthed Webcast

New Brain Health Guidelines – What GPs Can Do

Tuesday 4th August, 7pm - 9pm AEST

Speaker

Scientia Prof Kaarin Anstey

Psychologist; Director, UNSW Ageing Futures Institute; ARC Laureate Fellow; Senior Principal Research Scientist, NeuRA

Scientia Prof Kaarin Anstey translates the WHO's updated 2026 dementia risk-reduction guidelines changes into concrete actions for opportunistic risk assessment and targeted advice in everyday general practice.

Dr Nigel Strauss

Psychiatrist and Clinical Associate at The Centre of Mental Health, Swinburne University of Technology

More from this expert

Psychedelic medicine is on its way. Here’s what you need to know

Many people in Australia, including psychiatrists, were surprised when earlier this year the medicines regulator down-scheduled MDMA, known colloquially as ecstasy, and psilocybin, from magic mushrooms.

Psychedelic medicine is on its way. Here’s what you need to know

Many people in Australia, including psychiatrists, were surprised when earlier this year the medicines regulator down-scheduled MDMA, known colloquially as ecstasy, and psilocybin, from magic mushrooms.

Save time on registrations, track CPD, listen to full podcasts... sign in to your Healthed account now

Don't have an existing account? Sign up today

Sign up for a free Healthed account

Extra Details

PASSWORD RESET

Discover

Healthed

Upcoming Healthed Webcast

New Brain Health Guidelines – What GPs Can Do

Tuesday 4th August, 7pm - 9pm AEST

Speaker

Scientia Prof Kaarin Anstey

Psychologist; Director, UNSW Ageing Futures Institute; ARC Laureate Fellow; Senior Principal Research Scientist, NeuRA

Scientia Prof Kaarin Anstey translates the WHO's updated 2026 dementia risk-reduction guidelines changes into concrete actions for opportunistic risk assessment and targeted advice in everyday general practice.